These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37517865)

  • 21. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
    Takashima K; Morrison M; Minari J
    Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A changing time: the International Society for Cellular Therapy embraces its industry members.
    Deans R; Gunter KC; Allsopp T; Bonyhadi M; Burger SR; Carpenter M; Clark T; Cox CS; Driscoll D; Field E; Huss R; Lardenoije R; Lodie TA; Mason C; Neubiser R; Rasko JE; Rowley J; Maziarz RT
    Cytotherapy; 2010 Nov; 12(7):853-6. PubMed ID: 20942603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
    Marti A
    Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon.
    Chisholm J; Ruff C; Viswanathan S
    Cytotherapy; 2019 Jul; 21(7):686-698. PubMed ID: 31196821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Marketing authorisation for rare diseases: The European regulatory perspective using the example of gene and cell therapies].
    Schüßler-Lenz M; Hofner B
    Z Evid Fortbild Qual Gesundhwes; 2024 Sep; 189():73-81. PubMed ID: 39242221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era.
    Erikainen S; Couturier A; Chan S
    Sci Cult (Lond); 2020; 29(2):219-244. PubMed ID: 33716572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proceedings of the signature series symposium "cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies-promise, facts and fantasy," international society for cellular therapies, montreal, canada, may 2, 2018.
    Piuzzi NS; Dominici M; Long M; Pascual-Garrido C; Rodeo S; Huard J; Guicheux J; McFarland R; Goodrich LR; Maddens S; Robey PG; Bauer TW; Barrett J; Barry F; Karli D; Chu CR; Weiss DJ; Martin I; Jorgensen C; Muschler GF
    Cytotherapy; 2018 Nov; 20(11):1381-1400. PubMed ID: 30316562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy Products.
    Hayakawa T; Harris I; Joung J; Kanai N; Kawamata S; Kellathur S; Koga J; Lin YC; Maruyama Y; McBlane J; Nishimura T; Renner M; Ridgway A; Salmikangas P; Sakamoto N; Sato D; Sato Y; Toda Y; Umezawa A; Werner M; Wicks S
    Biologicals; 2016 Sep; 44(5):467-79. PubMed ID: 27461129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
    Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies.
    Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC
    Regen Med; 2023 Oct; 18(10):781-793. PubMed ID: 37795701
    [No Abstract]   [Full Text] [Related]  

  • 34. Academic physician specialists' views toward the unproven stem cell intervention industry: areas of common ground and divergence.
    Smith C; Crowley A; Munsie M; DeMartino ES; Staff NP; Shapiro S; Master Z
    Cytotherapy; 2021 Apr; 23(4):348-356. PubMed ID: 33563545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model.
    Viswanathan S; Rao M; Keating A; Srivastava A
    Stem Cells Transl Med; 2013 Aug; 2(8):607-13. PubMed ID: 23836804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
    Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
    Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.
    Master Z; Fu W; Paciulli D; Sipp D
    Clin Pharmacol Ther; 2017 Aug; 102(2):177-179. PubMed ID: 28695633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea.
    Choi M; Han E; Lee S; Kim T; Shin W
    Adv Exp Med Biol; 2015; 871():163-79. PubMed ID: 26374218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union.
    Narayanan G; Cossu G; Galli MC; Flory E; Ovelgonne H; Salmikangas P; Schneider CK; Trouvin JH
    Hum Gene Ther Clin Dev; 2014 Mar; 25(1):1-6. PubMed ID: 24649836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.